Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
November 10, 2021 07:30 ET
|
Decibel Therapeutics, Inc.
- Received Orphan Drug and Rare Pediatric Disease designations for DB-OTO for the treatment of otoferlin-related congenital hearing loss – - On track for key 2022 milestones including submission of...
Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit
November 08, 2021 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
September 09, 2021 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary
August 18, 2021 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
August 10, 2021 07:30 ET
|
Decibel Therapeutics, Inc.
- Bolstered Board of Directors and Scientific Advisory Board with key appointments - - On track for anticipated 2022 milestones including submission of IND and/or CTA for DB-OTO and interim...
Decibel Therapeutics Appoints Dr. William H. Carson as Chairman of the Board of Directors
June 02, 2021 08:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference
May 19, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 08, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
March 29, 2021 16:05 ET
|
Decibel Therapeutics, Inc.
-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds- -Established development and manufacturing agreement...
Decibel Therapeutics Added to Russell 2000 Index
March 22, 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, March 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments...